Natera, Inc.

Natera, Inc. is a diagnostics company that utilizes proprietary molecular and bioinformatics technology to manage diseases globally. The company's cell-free DNA (cfDNA) technology integrates novel molecular assays, which accurately measure numerous informative regions across the genome from samples as small as a single cell, with statistical algorithms that incorporate scientific data to identify genetic variations for a wide range of serious conditions with high accuracy and coverage. Natera aims to integrate personalized genetic testing and diagnostics into standard medical care to protect health and enable earlier, more targeted interventions. The company applies its technology across three primary healthcare areas: oncology, women's health, and organ health. Since 2009, Natera has introduced a comprehensive suite of products to enhance patient care outcomes in these fields. In oncology, Natera commercializes personalized blood-based DNA tests to optimize therapy decisions from diagnosis through survivorship. For women's health, the company develops and commercializes non- or minimally-invasive tests for needs ranging from prenatal testing to hereditary cancer screening. In organ health, Natera provides tests to assess kidney, heart, and lung transplant rejection, alongside genetic testing for chronic kidney disease. Natera operates with a direct sales force in the United States and a global network of over 100 laboratory and distribution partners, including several large international laboratories. As of December 31, 2025, the company had over 350 peer-reviewed publications and over 650 issued or pending patents. Natera's revenues were $2,306.1 million in 2025, compared to $1,696.9 million in 2024 and $1,082.6 million in 2023.